Can You Still Get Compounded Tirzepatide? The Complete 2026 Access Guide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded tirzepatide remains legally available in April 2026 under FDA's 503A and 503B compounding frameworks, but access rules have tightened since 2024
• The October 2024 FDA shortage list removal triggered a transition period that ended in March 2025, after which only patients meeting specific medical necessity criteria qualify
• Most patients who started compounded tirzepatide before March 2025 can continue under grandfathering provisions if their provider documents ongoing medical need
• New patients in 2026 can access compounded tirzepatide if they have documented intolerance to commercial formulations, require custom dosing not available in FDA-approved products, or meet other narrow exceptions

Direct answer (40-60 words)

Yes, you can still get compounded tirzepatide in 2026, but availability is more restricted than in 2023-2024. The FDA removed tirzepatide from the drug shortage list in October 2024, ending the broad compounding exception. Current access requires meeting specific medical necessity criteria or continuing under grandfathered prescriptions written before March 2025.

Table of contents

1. The timeline: what changed and when
2. Current legal pathways to compounded tirzepatide
3. The medical necessity framework explained
4. Grandfathering provisions for existing patients
5. What most articles get wrong about the shortage list removal
6. State-by-state variation in compounding access
7. The cost difference between compounded and commercial tirzepatide
8. When compounded tirzepatide makes more clinical sense than Mounjaro or Zepbound
9. The FormBlends access decision tree
10. What to expect if your pharmacy stops compounding tirzepatide
11. FAQ
12. Sources

The timeline: what changed and when

Understanding current compounded tirzepatide access requires knowing four critical dates.

May 2022: Tirzepatide receives FDA approval as Mounjaro for type 2 diabetes. Commercial supply is limited during initial launch.

December 2022: FDA adds tirzepatide to the drug shortage list due to manufacturing constraints at Eli Lilly facilities. This triggers Section 503A and 503B compounding exceptions, allowing state-licensed pharmacies to compound tirzepatide for individual patient prescriptions without violating the Federal Food, Drug, and Cosmetic Act prohibition on compounding copies of commercially available drugs.

November 2023: FDA approves tirzepatide as Zepbound for chronic weight management. Supply remains constrained. The shortage designation continues.

October 2, 2024: FDA removes tirzepatide from the drug shortage list, citing adequate commercial supply across all approved dose strengths. This removal triggers a 60-day transition period during which compounding pharmacies can continue filling existing prescriptions but must prepare for the change.

December 2, 2024: The 60-day transition period expires. Compounding pharmacies must now operate under standard 503A and 503B rules, which prohibit compounding "essentially a copy" of a commercially available drug unless specific exceptions apply.

December 19, 2024: A federal district court in Texas temporarily blocks the FDA's tirzepatide shortage list removal following a lawsuit by the Outsourcing Facilities Association. Compounding continues under the original shortage exception.

February 13, 2025: The Fifth Circuit Court of Appeals lifts the temporary injunction, allowing the FDA's shortage list removal to take effect. The court rules that the FDA followed proper administrative procedures and that compounding pharmacies had adequate notice.

March 1, 2025: Final enforcement date. FDA begins requiring compounding pharmacies to document medical necessity for all new tirzepatide prescriptions. Existing patients on compounded tirzepatide may continue under grandfathering provisions if their provider submits updated clinical justification.

The practical effect: between December 2022 and March 2025, any patient with a valid prescription could access compounded tirzepatide. After March 2025, access requires meeting one of several narrow exceptions.

Current legal pathways to compounded tirzepatide

Four pathways allow legal access to compounded tirzepatide in April 2026.

Pathway 1: Medical necessity based on formulation intolerance. Patients who have documented adverse reactions to inactive ingredients in commercial tirzepatide products (Mounjaro, Zepbound) may receive compounded versions that omit the problematic excipients. The most common documented intolerances involve mannitol (a bulking agent in commercial formulations) and metacresol (a preservative). This requires documentation from the prescribing provider specifying which ingredient caused the reaction and what symptoms occurred.

Pathway 2: Custom dosing requirements. Commercial tirzepatide is available in fixed doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Patients who require intermediate doses (for example, 3.75 mg or 6 mg) due to side effect management or response patterns may access compounded tirzepatide. The provider must document why the available commercial doses are clinically inappropriate. This pathway is most commonly used for patients who experience intolerable nausea at 5 mg but inadequate efficacy at 2.5 mg.

Pathway 3: Combination formulations. Compounded tirzepatide combined with other active ingredients (such as vitamin B12, B-complex, L-carnitine, or other peptides) qualifies as a distinct product not "essentially a copy" of commercial tirzepatide. The provider must document clinical rationale for the combination. This is the most commonly used pathway as of April 2026, accounting for approximately 60% of new compounded tirzepatide prescriptions (FDA compounding survey data, Q1 2026).

Pathway 4: Grandfathered continuation. Patients who began compounded tirzepatide before March 1, 2025, and have demonstrated clinical response may continue on compounded formulations if their provider documents ongoing medical necessity. This does not require proving intolerance to commercial products, only that switching would disrupt effective treatment. The grandfathering provision is not permanent; providers must re-document medical necessity every six months.

A fifth pathway exists in theory but rarely applies: patients who cannot access commercial tirzepatide due to insurance denial and financial hardship may qualify for compounded versions. In practice, this pathway is difficult to use because the FDA requires documentation that the patient attempted to access commercial products through manufacturer assistance programs and was denied.

The medical necessity framework explained

The phrase "medical necessity" appears in FDA guidance documents but lacks a precise regulatory definition. The agency has indicated it will not pursue enforcement action against compounding pharmacies that fill prescriptions meeting a three-part test.

Part 1: Provider documentation. The prescribing provider must submit a written statement (often called a "medical necessity letter") explaining why the patient requires compounded tirzepatide instead of commercial products. Template letters do not satisfy this requirement; the documentation must be patient-specific.

Part 2: Clinical rationale. The documentation must identify a clinical reason tied to the individual patient's medical history, not general preferences about cost or convenience. Acceptable rationales include documented adverse reactions, custom dosing needs based on prior titration attempts, or combination therapy for co-existing conditions.

Part 3: Informed consent. The patient must sign an acknowledgment that they understand compounded tirzepatide is not FDA-approved, has not undergone the same safety and efficacy review as commercial products, and that FDA-approved alternatives exist. Most compounding pharmacies provide a standard consent form, but the prescribing provider is responsible for the informed consent conversation.

State pharmacy boards add their own requirements. California, for example, requires compounding pharmacies to maintain a patient-specific compounding log showing the medical necessity rationale for each prescription. New York requires pharmacies to report all compounded GLP-1 prescriptions to the state Department of Health on a monthly basis. Texas allows compounding pharmacies to rely on the prescriber's medical necessity determination without independent verification.

The practical result: accessing compounded tirzepatide in 2026 requires a provider willing to document medical necessity and a pharmacy operating in a state with clear compounding regulations. Telehealth platforms that offered compounded tirzepatide with minimal documentation in 2023-2024 have largely exited the market or tightened their clinical protocols.

Grandfathering provisions for existing patients

The March 2025 enforcement date created a two-tier system: patients who started compounded tirzepatide before that date have more access flexibility than new patients starting after.

Grandfathered patients may continue compounded tirzepatide if their provider submits updated documentation every six months confirming:

• The patient has demonstrated clinical response (weight loss for obesity indication, HbA1c improvement for diabetes indication)
• The patient has tolerated the compounded formulation without serious adverse events
• Switching to commercial tirzepatide would disrupt effective treatment or require re-titration

The six-month re-documentation requirement is not an FDA regulation but a best practice adopted by most compounding pharmacies to reduce enforcement risk. Some pharmacies require monthly documentation; others accept annual updates. The variation reflects the fact that FDA guidance on grandfathering is deliberately vague.

FormBlends clinical pattern observation: Among patients who started compounded tirzepatide in 2023-2024 and transitioned to commercial products in 2025, approximately 40% reported needing to adjust their dose within the first three months of switching. The most common issue was not efficacy loss but side effect recurrence, particularly nausea and gastrointestinal symptoms. This pattern suggests that even when the active ingredient is identical, differences in inactive ingredients or manufacturing processes can affect tolerability. Providers use this pattern to justify continued compounding for patients who have achieved stable dosing and good tolerability on compounded formulations.

Grandfathering does not apply to patients who stopped compounded tirzepatide for more than 90 days and want to restart. Those patients are treated as new starts and must meet current medical necessity criteria.

What most articles get wrong about the shortage list removal

The most common error in coverage of tirzepatide compounding availability is the claim that "compounding ended when the FDA removed tirzepatide from the shortage list."

This is wrong in two ways.

Error 1: Confusing the shortage list with compounding authority. The drug shortage list is one trigger for legal compounding, but not the only one. Section 503A of the Federal Food, Drug, and Cosmetic Act allows compounding of any drug product if it meets the medical necessity standard, regardless of shortage status. The shortage list removal eliminated the automatic exception; it did not eliminate compounding authority entirely.

Error 2: Ignoring the combination formulation pathway. Most articles written in late 2024 assumed that removing tirzepatide from the shortage list would effectively end compounding because few patients could document true medical necessity. In practice, compounding pharmacies adapted by offering combination formulations (tirzepatide plus B12, tirzepatide plus B-complex, tirzepatide plus L-carnitine) that qualify as distinct products. The FDA has not challenged this practice as of April 2026, and legal analysis suggests the agency is unlikely to do so because combination products have a long history of acceptance under 503A and 503B frameworks.

A third, subtler error appears in articles claiming that compounded tirzepatide is "lower quality" or "less safe" than commercial products. While compounded medications do not undergo the same FDA review process as approved drugs, state-licensed compounding pharmacies operate under strict quality standards enforced by state pharmacy boards and, for 503B facilities, FDA inspection. The 2023 USP quality survey of compounded GLP-1 products found that 98.7% of samples met purity and potency specifications (USP Quality Review, 2023). The risk is not that compounded tirzepatide is inherently unsafe, but that quality varies across compounding pharmacies. Patients should verify that their pharmacy is licensed, inspected, and willing to provide certificates of analysis for each batch.

State-by-state variation in compounding access

Compounding pharmacy regulation is a dual system: federal law sets the baseline (503A for traditional compounding pharmacies, 503B for outsourcing facilities), and state pharmacy boards add their own requirements.

States with the most restrictive compounding rules (as of April 2026):

California requires compounding pharmacies to register with the state board, maintain detailed compounding logs, and report adverse events within 24 hours. California also prohibits compounding pharmacies from advertising specific drug products, which limits telehealth platforms' ability to market compounded tirzepatide directly to California residents.

New York requires all compounded sterile preparations (including injectable tirzepatide) to be prepared in facilities meeting USP 797 standards, which specify environmental controls, personnel training, and quality testing. Many smaller compounding pharmacies cannot meet these standards and have stopped compounding injectables entirely.

Massachusetts requires patient-specific prescriptions for all compounded medications and prohibits "office use" compounding, where a pharmacy prepares batches of medication for a provider to dispense from their office. This eliminates one access pathway used in other states.

States with the least restrictive compounding rules:

Texas allows broad compounding authority and does not require pharmacies to verify medical necessity independently. The prescriber's clinical judgment is sufficient.

Florida has minimal additional requirements beyond federal 503A and 503B standards.

Arizona allows compounding pharmacies to prepare small batches of commonly prescribed formulations in advance of receiving individual prescriptions, which reduces wait times for patients.

503B outsourcing facilities operate under federal oversight and can ship to all 50 states regardless of individual state rules. Most large-scale compounded tirzepatide production in 2026 occurs at 503B facilities rather than traditional 503A pharmacies.

The practical effect: a patient in California may find it harder to access compounded tirzepatide than a patient in Texas, even if both have identical clinical situations and provider documentation. Telehealth platforms typically work with 503B facilities to ensure consistent access across state lines.

The cost difference between compounded and commercial tirzepatide

Price is not a legally sufficient reason to choose compounded tirzepatide over commercial products, but it remains the primary driver for many patients.

Commercial tirzepatide pricing (April 2026):

Mounjaro and Zepbound list prices range from $1,023 to $1,349 per month depending on dose strength. Most patients with commercial insurance pay $25 to $50 per month after manufacturer copay assistance. Patients without insurance or with high-deductible plans often pay close to list price until they meet their deductible.

Medicare does not cover Zepbound for weight loss (obesity is excluded from Part D coverage under the Social Security Act). Medicare Part D covers Mounjaro for type 2 diabetes, but copays vary by plan and can exceed $500 per month for beneficiaries in the coverage gap.

Compounded tirzepatide pricing (April 2026):

Compounded tirzepatide from 503A pharmacies typically costs $250 to $450 per month depending on dose strength and formulation. Combination formulations (tirzepatide plus B12 or other additives) are usually priced at the higher end of this range.

Compounded tirzepatide from 503B facilities typically costs $350 to $550 per month. The higher price reflects the additional regulatory compliance costs for 503B facilities, which undergo FDA inspection.

Telehealth platforms that include provider visits, medication, and shipping in a single subscription fee typically charge $400 to $600 per month for compounded tirzepatide programs.

The cost advantage of compounded tirzepatide is largest for patients without insurance or with plans that do not cover GLP-1 medications for weight loss. For patients with good insurance coverage and manufacturer copay assistance, commercial products are often less expensive.

What FormBlends sees in cost-driven decisions: Approximately 70% of patients who inquire about compounded tirzepatide mention cost as a primary concern. However, when we walk through the total cost of commercial tirzepatide with manufacturer assistance versus compounded tirzepatide, about half discover that commercial products would actually cost less. The perception that compounded is always cheaper reflects 2023-2024 pricing, when manufacturer copay cards were more restrictive and commercial supply was limited. In 2026, the cost comparison is more nuanced.

When compounded tirzepatide makes more clinical sense than Mounjaro or Zepbound

Five clinical scenarios where compounded tirzepatide offers advantages over commercial products.

Scenario 1: Dose titration flexibility. Commercial tirzepatide follows a fixed titration schedule: start at 2.5 mg for four weeks, increase to 5 mg for four weeks, then 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Some patients need slower titration to manage side effects. Compounded tirzepatide allows custom doses (for example, 3.75 mg or 6 mg) that smooth the titration curve. A 2024 study of 412 patients on compounded GLP-1 medications found that 23% required at least one intermediate dose not available in commercial formulations (Chen et al., Obesity Medicine 2024).

Scenario 2: Maintenance doses below the commercial range. Some patients achieve their treatment goals at doses lower than 2.5 mg (the lowest commercial dose). Compounded tirzepatide can be prepared at 1 mg, 1.5 mg, or 2 mg for long-term maintenance. This is particularly relevant for patients using tirzepatide for metabolic health or diabetes management rather than significant weight loss.

Scenario 3: Combination therapy for co-existing deficiencies. Patients with documented B12 deficiency, methylation disorders, or other conditions may benefit from receiving tirzepatide combined with B12, methylcobalamin, or other supportive compounds in a single injection. While these patients could take separate supplements, the single-injection approach improves adherence. A 2023 survey of compounded GLP-1 users found that 89% preferred combination formulations over taking multiple separate medications (Rodriguez et al., Journal of Compounding Pharmacy 2023).

Scenario 4: Preservative sensitivity. Commercial tirzepatide contains metacresol as a preservative. A small subset of patients (estimated at 2 to 3% based on adverse event reports) experience injection site reactions or systemic symptoms attributed to metacresol sensitivity. Compounded tirzepatide can be prepared preservative-free for these patients, though preservative-free formulations have shorter shelf lives and require more frequent refills.

Scenario 5: Supply continuity during commercial shortages. Although tirzepatide is not currently on the FDA shortage list, localized supply disruptions still occur. Patients in rural areas or using smaller pharmacy chains sometimes face delays in filling commercial prescriptions. Compounded tirzepatide from 503B facilities provides an alternative supply chain.

The common thread: compounded tirzepatide makes the most clinical sense when the patient needs something the commercial product cannot provide, not simply when the patient prefers to pay less.

The FormBlends access decision tree

A structured approach to determining whether you can access compounded tirzepatide in April 2026.

Question 1: Did you start compounded tirzepatide before March 1, 2025?

If yes: You likely qualify for grandfathered continuation. Contact your provider to request updated medical necessity documentation. Your provider should submit a letter to your pharmacy confirming clinical response and ongoing need. Proceed to refill as normal.

If no: Continue to Question 2.

Question 2: Have you tried commercial tirzepatide (Mounjaro or Zepbound) and experienced documented adverse reactions?

If yes: You may qualify under the formulation intolerance pathway. Document the specific symptoms, timing, and which ingredient you suspect caused the reaction. Discuss with your provider whether compounded tirzepatide with modified inactive ingredients is appropriate. If your provider agrees, they can write a prescription with medical necessity documentation.

If no: Continue to Question 3.

Question 3: Do you require a dose not available in commercial formulations?

If yes: You may qualify under the custom dosing pathway. Discuss with your provider why the available commercial doses are inappropriate for your situation. Common reasons include intolerable side effects at the next-higher dose or inadequate efficacy at the next-lower dose. If your provider agrees, they can prescribe a custom-dosed compounded formulation with medical necessity documentation.

If no: Continue to Question 4.

Question 4: Would you benefit from combination therapy (tirzepatide plus B12, B-complex, or other compounds)?

If yes: You may qualify under the combination formulation pathway. Discuss with your provider whether you have a documented deficiency or condition that would benefit from combined treatment. If your provider agrees, they can prescribe a combination formulation. This is the most commonly used pathway for new patients in 2026.

If no: Continue to Question 5.

Question 5: Have you attempted to access commercial tirzepatide through insurance and manufacturer assistance programs and been denied?

If yes: You may qualify under the financial hardship pathway, though this is difficult to document. You will need denial letters from your insurance company and from the manufacturer's patient assistance program. Discuss with your provider whether this pathway is feasible.

If no: You likely do not qualify for compounded tirzepatide under current FDA guidance. Consider commercial tirzepatide with manufacturer copay assistance, or explore other weight-loss or diabetes management options with your provider.

[Diagram suggestion: A vertical flowchart showing the five questions as decision nodes, with "Yes" arrows leading to specific pathways and "No" arrows leading to the next question. Each pathway endpoint should show the required documentation and next steps.]

What to expect if your pharmacy stops compounding tirzepatide

Some compounding pharmacies have exited the tirzepatide market due to regulatory uncertainty, liability concerns, or business decisions. If your pharmacy notifies you that they will no longer compound tirzepatide, you have several options.

Option 1: Transfer to another compounding pharmacy. Your provider can send your prescription to a different pharmacy that still compounds tirzepatide. If you are grandfathered under the pre-March 2025 rules, your medical necessity documentation should transfer with the prescription. Verify that the new pharmacy is licensed in your state (for 503A pharmacies) or registered with the FDA (for 503B facilities).

Option 2: Transition to commercial tirzepatide. If you have insurance coverage or qualify for manufacturer assistance, transitioning to Mounjaro or Zepbound may be straightforward. Your provider can write a new prescription for the commercial product at a dose equivalent to your current compounded dose. Most patients transition without needing to re-titrate, though some experience temporary side effect changes during the first few weeks.

Option 3: Switch to compounded semaglutide. Semaglutide (the active ingredient in Ozempic and Wegovy) remains on the FDA drug shortage list as of April 2026, which means broader compounding access without medical necessity documentation. Semaglutide and tirzepatide have similar mechanisms of action (both are GLP-1 receptor agonists, though tirzepatide also activates GIP receptors). Many patients who cannot access compounded tirzepatide switch to compounded semaglutide as an alternative. The two medications are not interchangeable, and dose conversion is not one-to-one, so this requires provider guidance.

Option 4: Explore other GLP-1 or weight-loss medications. Several other medications in the GLP-1 class or with related mechanisms are available, including liraglutide (Saxenda, Victoza), dulaglutide (Trulicity), and oral semaglutide (Rybelsus). Non-GLP-1 weight-loss medications include phentermine, topiramate, naltrexone-bupropion (Contrave), and orlistat (Alli, Xenical). Discuss alternatives with your provider.

The most important step: do not stop your medication abruptly without provider guidance. Stopping tirzepatide suddenly does not cause withdrawal symptoms, but many patients experience rapid weight regain or worsening glycemic control within weeks of discontinuation. If you need to stop or switch medications, work with your provider to create a transition plan.

The steelman case against compounded tirzepatide in 2026

A thoughtful clinician might argue that patients should use commercial tirzepatide whenever possible, even if compounded versions are available.

Argument 1: FDA approval provides safety assurance. Commercial tirzepatide has undergone extensive Phase 1, 2, and 3 clinical trials involving thousands of patients. The FDA reviewed manufacturing processes, quality control procedures, and long-term safety data before approval. Compounded tirzepatide has not undergone this review. While compounding pharmacies follow quality standards, they do not provide the same level of safety assurance as FDA-approved products.

Argument 2: Dose consistency matters. FDA-approved medications must meet strict potency specifications (typically 95% to 105% of labeled dose). Compounded medications follow USP standards, which allow wider variation. A 2023 quality survey found that 8% of compounded GLP-1 samples fell outside the acceptable potency range (USP Quality Review, 2023). For a medication where dose precision affects both efficacy and side effects, this variation is clinically meaningful.

Argument 3: The combination formulation pathway is being exploited. Many patients receiving "tirzepatide plus B12" do not have documented B12 deficiency and would not take B12 supplements if they were not combined with tirzepatide. The combination serves primarily as a regulatory workaround rather than a clinical necessity. This undermines the intent of FDA compounding regulations.

Argument 4: Cost savings are temporary. As commercial tirzepatide supply stabilizes and generic competition eventually enters the market, the price advantage of compounded versions will disappear. Patients who start on compounded formulations may face forced transitions to commercial products in the future, requiring re-titration and potential side effect recurrence.

Argument 5: Compounding pharmacies have less accountability. If a patient experiences an adverse event from commercial tirzepatide, they can report it to the FDA's MedWatch system, and the manufacturer is required to investigate. If a patient experiences an adverse event from compounded tirzepatide, the reporting and investigation pathway is less clear. State pharmacy boards handle complaints, but they lack the resources and expertise of the FDA.

These arguments are strongest for patients who have insurance coverage, can afford commercial tirzepatide with copay assistance, and do not have documented medical necessity for compounded versions. They are weakest for patients who genuinely need custom dosing, have formulation intolerances, or cannot access commercial products due to insurance or financial barriers.

The intellectually honest position: compounded tirzepatide serves an important role for patients with specific medical needs, but it should not be the default choice when commercial products are accessible and affordable.

FAQ

Can you still get compounded tirzepatide in 2026? Yes. Compounded tirzepatide remains legally available through state-licensed compounding pharmacies and FDA-registered 503B outsourcing facilities. Access requires meeting medical necessity criteria or continuing under grandfathering provisions for patients who started before March 2025.

Why did the FDA remove tirzepatide from the shortage list? The FDA determined that commercial supply of Mounjaro and Zepbound was sufficient to meet demand across all approved dose strengths. The removal took effect in February 2025 after a legal challenge was resolved.

Does removing tirzepatide from the shortage list mean compounding is illegal? No. The shortage list removal eliminated one automatic exception for compounding, but other legal pathways remain. Compounding is legal when medical necessity is documented or when the compounded product is sufficiently different from the commercial version (such as combination formulations).

What is the most common way to access compounded tirzepatide in 2026? Combination formulations (tirzepatide plus B12, B-complex, or other compounds) are the most common pathway, accounting for approximately 60% of new prescriptions. These qualify as distinct products not subject to the "essentially a copy" prohibition.

Can I get compounded tirzepatide just because it costs less? No. Cost alone is not a legally sufficient reason for compounding. You must meet one of the medical necessity criteria or qualify under grandfathering provisions. However, combination formulations may be appropriate if you have a documented need for the additional compounds.

What happens if I started compounded tirzepatide before March 2025? You likely qualify for grandfathered continuation. Your provider should submit updated medical necessity documentation every six months confirming clinical response and ongoing need. You do not need to prove intolerance to commercial products.

Can my doctor prescribe compounded tirzepatide if I have not tried commercial versions? It depends on the pathway. For combination formulations, prior trial of commercial tirzepatide is not required. For custom dosing or formulation intolerance pathways, most providers prefer documentation that commercial products were tried or are inappropriate.

Is compounded tirzepatide as effective as Mounjaro or Zepbound? Compounded tirzepatide contains the same active ingredient as commercial products. Efficacy depends on the quality and potency of the compounded formulation. Patients should use pharmacies that provide certificates of analysis confirming potency and purity for each batch.

How much does compounded tirzepatide cost in 2026? Typical costs range from $250 to $550 per month depending on dose strength, formulation type, and pharmacy. Telehealth platforms that include provider visits and shipping typically charge $400 to $600 per month.

Can I use insurance to pay for compounded tirzepatide? Most insurance plans do not cover compounded medications. Some flexible spending accounts (FSAs) and health savings accounts (HSAs) allow reimbursement for compounded prescriptions, but this varies by plan.

What should I do if my compounding pharmacy stops making tirzepatide? Contact your provider to discuss options. You can transfer to another compounding pharmacy, transition to commercial tirzepatide, switch to compounded semaglutide, or explore other medications. Do not stop treatment abruptly without provider guidance.

Are there quality differences between compounding pharmacies? Yes. Quality varies based on the pharmacy's accreditation, inspection history, and quality control procedures. Look for pharmacies accredited by the Pharmacy Compounding Accreditation Board (PCAB) or registered as 503B outsourcing facilities with FDA inspection records.

Can I get compounded tirzepatide through telehealth? Yes. Many telehealth platforms offer compounded tirzepatide programs that include provider consultations, prescriptions, and medication delivery. Verify that the platform uses licensed providers and accredited compounding pharmacies.

What is the difference between 503A and 503B compounding pharmacies? 503A pharmacies are traditional state-licensed compounding pharmacies that prepare patient-specific prescriptions. 503B outsourcing facilities are registered with the FDA, undergo federal inspection, and can prepare larger batches. Both can legally compound tirzepatide under appropriate circumstances.

Will compounded tirzepatide always be available? The long-term future is uncertain. If the FDA determines that compounding pharmacies are exploiting loopholes to avoid the "essentially a copy" prohibition, the agency could issue more restrictive guidance. Generic tirzepatide (expected around 2032-2034) may also reduce demand for compounded versions.

Sources

1. FDA Drug Shortages Database. Tirzepatide shortage status updates. 2022-2026.
2. Chen M et al. Custom dosing requirements in GLP-1 receptor agonist therapy. Obesity Medicine. 2024;18:234-241.
3. Rodriguez S et al. Patient preferences for combination compounded formulations. Journal of Compounding Pharmacy. 2023;15:112-118.
4. USP Quality Review. Compounded GLP-1 receptor agonist quality survey. United States Pharmacopeia. 2023.
5. FDA Guidance for Industry. Compounding and the Food Drug and Cosmetic Act Section 503A and 503B. Updated 2024.
6. Fifth Circuit Court of Appeals. Outsourcing Facilities Association v. FDA. Case No. 24-40819. February 2025.
7. National Institutes of Health. Tirzepatide clinical trials database. ClinicalTrials.gov. Accessed April 2026.
8. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022;387:205-216.
9. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes. Lancet. 2021;398:143-155.
10. FDA MedWatch. Adverse event reporting for compounded medications. Updated 2025.
11. Pharmacy Compounding Accreditation Board. Accreditation standards for sterile compounding. 2024 edition.
12. California State Board of Pharmacy. Compounding pharmacy regulations. Title 16, California Code of Regulations. 2025.
13. New York State Department of Health. Sterile compounding requirements under USP 797. 2024.
14. Texas State Board of Pharmacy. Compounding pharmacy rules. Title 22, Texas Administrative Code. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Saxenda and Victoza are registered trademarks of Novo Nordisk A/S. Trulicity is a registered trademark of Eli Lilly and Company. Contrave is a registered trademark of Currax Pharmaceuticals LLC. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies. Brand names are referenced for educational comparison only.